Eagle's Eye View: Your Weekly CV Update From ACC.org Top Six Trials From AHA 2024: BROAD, SUMMIT, OPTION, CLEAR SYNERGY (Spironolactone and Colchicine), My Heart Your Heart
12 snips
Nov 21, 2024 Discover groundbreaking research from recent AHA sessions, like the BROAD trial focused on blood pressure control. Learn how tirzepatide from the SUMMIT study holds promise for obesity-related heart issues. The OPTION trial compares new stroke prevention methods in atrial fibrillation. Explore dual trials from CLEAR SYNERGY on spironolactone and colchicine for heart attack patients. Finally, hear about innovative uses for refurbished pacemakers in Project My Heart Your Heart.
AI Snips
Chapters
Transcript
Episode notes
Intensive BP Control in Diabetics
- In the BROAD trial, intensive blood pressure control (systolic BP < 120) in type 2 diabetics with elevated CV risk reduced MACE.
- Standard therapy targeted systolic BP < 140.
Tirzepatide for HFpEF and Obesity
- The SUMMIT trial showed that once-weekly tirzepatide improved outcomes and quality of life in obese patients with HFpEF.
- Patients also experienced improvements in Kansas City questionnaire scores.
LAA Closure vs. Anticoagulation
- The OPTION trial compared LAA closure to oral anticoagulation in post-ablation AFib patients.
- LAA closure resulted in less bleeding and similar efficacy in stroke prevention.